Your browser doesn't support javascript.
loading
[Pathological Features, Treatment Options and Prognosis Assessment of Patients with Bone Lymphoma in Real-World].
Ou, Jin-Ping; Gao, Shuang; Wang, Li-Hong; Zhang, Jian-Hua; Nong, Lin; Liu, Wei; Wang, Wen-Sheng; Sun, Yu-Hua; Xu, Wei-Lin; Yin, Yue; Liang, Ze-Yin; Wang, Qian; Li, Yuan; Dong, Yu-Jun; Wang, Qing-Yun; Wang, Mang-Ju; Wang, Bing-Jie; Qiu, Zhi-Xiang; Cen, Xi-Nan; Ren, Han-Yun.
Afiliación
  • Ou JP; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Gao S; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Wang LH; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Zhang JH; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Nong L; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Liu W; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Wang WS; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Sun YH; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Xu WL; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Yin Y; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Liang ZY; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Wang Q; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Li Y; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Dong YJ; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Wang QY; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Wang MJ; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Wang BJ; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Qiu ZX; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
  • Cen XN; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China,E-mail: cenxn@aliyun.com.
  • Ren HY; Department of Hematology, The First Hospital of Peking University, Beijing 100034, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 27(3): 796-801, 2019 Jun.
Article en Zh | MEDLINE | ID: mdl-31204934
OBJECTIVE: To investigate the clinical manifestations pathologic features, treatment options and prognosis of patients with bone lymphoma. METHODS: The clinical characteristics, pathologic features, treatment and prognosis of 34 BL patients diagnosed by histopathologic method or/and PET-CT and treated in first hospital of peking university from January 2004 to April 2018 were analyzed retrospectively. RESULTS: The median age of 34 BL patients was 56 years old, the male and female ratio was 1.43∶1 (24 /10). Among 34 patients, the patients with primary bone lymphoma(PBL) were 8 cases, the patients with secondary bone lymphoma(SBL) was 26 cases, the PBL and SBL ratio was 0.31∶1. Bone lymphoma lacks typical systemic symptoms, and its onset began mostly from bone pain and pathologic bone fracture. The most frequent pathological type of bone lymphoma in our study was diffuse large B-cell lymphoma (DLBCL), accounting for 55.88%. At present, the conventional treatment for bone lymphoma includes chemotherapy, or chemotherapy combined with radiotherapy and surgery, as well as hematopoietic stem cell transplantation. The average and median OS time of BL patients were 349 years and 3 years respectively, meanwhile the OS rate for three years and two years were 56.25% and 78.16%, respectively. Factors that affect survival of BL patients were PBL and SBL classification, pathological type, blood LDH level, and treatment methods. CONCLUSION: Bone lymphoma is usually concealed onset,an adequate and adequate combination therapy can improve the survival rate and transplantation therapy plays an important role. Primary bone lymphoma is rare, the prognosis of patients with primary bone lymphoma is good, whereas the prognosis of patients with secondary bone lymphoma is poor.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Linfoma de Células B Grandes Difuso / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Linfoma de Células B Grandes Difuso / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: Zh Revista: Zhongguo Shi Yan Xue Ye Xue Za Zhi Asunto de la revista: HEMATOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: China
...